Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.

Cancer biology & therapy - 1 Jul 2008

Wang Weixin, Figg William D

Abstract excerpt

Tumor suppressor BRCA1 and BRCA2 are frequently mutated in familial breast and ovarian cancer. More than ten percent of women with breast or ovarian cancer carry BRCA1 or BRCA2 (BRCA1/2) mutations. Cancers that arise in mutation carriers have often lost the wild-type allele through somatic alterations during tumor progression. BRCA1/2 play important roles in homologous recombination repair of DNA double-strand...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to DNA Repair

Share to Drug Resistance, Neoplasm

Share to Ovarian Neoplasms

Share to Protein Isoforms

Source

Open in PubMed Open full text

Identifiers

PMID: 18720553
DOI: 10.4161/cbt.7.7.6409
PMCID: PMC2731297

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.PMID 18720553Read ↗

Secondary mutations of BRCA1/2 and drug resistance.Semantic proximity Read ↗

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.Semantic proximity Read ↗

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.Semantic proximity Read ↗

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.Semantic proximity Read ↗

Secondary Somatic Mutations Restoring<i>BRCA1/2</i>Predict Chemotherapy Resistance in Hereditary Ovarian CarcinomasSemantic proximity Read ↗

Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion MutationsSemantic proximity Read ↗

BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challengesSemantic proximity Read ↗

Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.Semantic proximity Read ↗

RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC.Semantic proximity Read ↗

A comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors.Semantic proximity Read ↗

BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.Semantic proximity Read ↗

Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.